BioMarin Pharmaceutical (BMRN) News Today → Don’t make this retirement mistake (From Sasco Gold LLC) (Ad) Free BMRN Stock Alerts $82.94 +2.25 (+2.79%) (As of 06/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 7:26 PM | marketbeat.comArtia Global Partners LP Sells 49,580 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Artia Global Partners LP decreased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 63.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 28,885 shares of the biotechnology company's stock after selling 49,580 sharesJune 10 at 11:48 AM | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Up to $80.69BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Up to $80.69June 9 at 11:25 AM | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is Scout Investments Inc.'s 4th Largest PositionScout Investments Inc. lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 12.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 791,625 shares of the biotechJune 8 at 3:52 PM | marketbeat.comSectoral Asset Management Inc. Sells 95,020 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Sectoral Asset Management Inc. cut its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 65.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,070 shares of the biotechnology comJune 7 at 9:00 AM | prnewswire.comBioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 CongressJune 6, 2024 | marketbeat.comTop Biotech Stocks: Exploring Innovation Opportunities (BMRN)One fascinating sector to invest in is the biotech sector which includes companies involved in the research and development of therapeutics and vaccinesJune 6, 2024 | americanbankingnews.comBrokerages Set BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Target Price at $106.11June 5, 2024 | marketbeat.comCibc World Markets Corp Makes New $26.06 Million Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Cibc World Markets Corp purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 270,242 shares of the biotechnology company's stock, valued at approximately $26,057,000. CibJune 5, 2024 | investorplace.comJune's Biotech Boom: 3 Stocks to Buy for a Summertime SurgeJune 4, 2024 | marketbeat.comRhenman & Partners Asset Management AB Sells 97,500 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Rhenman & Partners Asset Management AB lowered its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 25.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 282,500 shares of the biotechnology compJune 3, 2024 | marketbeat.com35,901 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by APG Asset Management US Inc.APG Asset Management US Inc. acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 35,901 shares of the biotechnology company's stock, valuedJune 3, 2024 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Rating of "Moderate Buy" from BrokeragesBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-one analysts that are presently covering the company, Marketbeat reports. Nine analysts have rated the stock with a hold rating and twelve have issued a buy rating oJune 2, 2024 | insidertrades.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CFO Brian Mueller Sells 5,000 SharesJune 1, 2024 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Sells $3,043,733.50 in StockMay 31, 2024 | marketbeat.comInsider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CFO Sells $375,950.00 in StockBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) CFO Brian Mueller sold 5,000 shares of the company's stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $75.19, for a total value of $375,950.00. Following the completion of the sale, the chief financial officer now directly owns 72,159 shares of the company's stock, valued at $5,425,635.21. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.May 31, 2024 | marketbeat.comParnassus Investments LLC Sells 489,181 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Parnassus Investments LLC decreased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 20.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,849,348 shares of the biotechnology compaMay 31, 2024 | insidertrades.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP George Eric Davis Sells 40,850 SharesMay 30, 2024 | marketbeat.comWeiss Asset Management LP Acquires New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Weiss Asset Management LP acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 17,849 shares of the biotechnology company's stoMay 30, 2024 | marketbeat.comComgest Global Investors S.A.S. Acquires 22,313 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Comgest Global Investors S.A.S. grew its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 12.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 199,321 shares of the biotechnMay 29, 2024 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Hits New 12-Month Low at $73.69BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 12-Month Low at $73.69May 27, 2024 | finance.yahoo.comBioMarin Pharmaceutical (NASDAQ:BMRN) shareholders have endured a 15% loss from investing in the stock a year agoMay 27, 2024 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Franklin Resources Inc.Franklin Resources Inc. reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 46.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 301,764 shares of the biotechnology company's stock afterMay 26, 2024 | marketbeat.comDimensional Fund Advisors LP Buys 71,853 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Dimensional Fund Advisors LP boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 11.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 704,953 shares of the bioMay 24, 2024 | finance.yahoo.comBioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound?May 24, 2024 | marketbeat.comClearbridge Investments LLC Has $26.12 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Clearbridge Investments LLC cut its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 37.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 270,843 shares of the biotechnology company's stoMay 23, 2024 | marketbeat.comAssenagon Asset Management S.A. Sells 13,842 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Assenagon Asset Management S.A. cut its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 81.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,145 shares of the biotechnology company's stock after selling 13,8May 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and BioMarin Pharmaceutical (BMRN)May 23, 2024 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Sets New 12-Month Low at $75.03BioMarin Pharmaceutical (NASDAQ:BMRN) Hits New 1-Year Low at $75.03May 21, 2024 | marketbeat.comNorges Bank Purchases Shares of 3,361,310 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Norges Bank purchased a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 3,361,310 shares of the biotechnology company's sMay 19, 2024 | marketbeat.comING Groep NV Takes $20.25 Million Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)ING Groep NV purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 210,000 shares of the biotechnology company's stockMay 18, 2024 | wsj.comBioMarin Pharmaceutical Inc.May 18, 2024 | marketbeat.comBaird R W Downgrades BioMarin Pharmaceutical (NASDAQ:BMRN) to HoldBaird R W cut shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Friday.May 17, 2024 | msn.comBaird Downgrades BioMarin Pharmaceutical (BMRN)May 17, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS)May 17, 2024 | marketbeat.comRobert W. Baird Downgrades BioMarin Pharmaceutical (NASDAQ:BMRN) to NeutralRobert W. Baird downgraded shares of BioMarin Pharmaceutical from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $104.00 to $72.00 in a report on Friday.May 16, 2024 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to Post Q2 2024 Earnings of $0.36 Per Share, Zacks Research ForecastsBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities researchers at Zacks Research cut their Q2 2024 EPS estimates for shares of BioMarin Pharmaceutical in a report released on Monday, May 13th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will posMay 15, 2024 | seekingalpha.comBioMarin: Short-Term Headwinds But Long-Term Opportunities RemainMay 15, 2024 | marketbeat.comZacks Research Analysts Raise Earnings Estimates for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities researchers at Zacks Research upped their Q3 2024 earnings per share estimates for shares of BioMarin Pharmaceutical in a research note issued on Monday, May 13th. Zacks Research analyst S. Ganoria now expects that the biotechnolMay 14, 2024 | bizjournals.comBioMarin cutting about 170 jobs after shuffling drug portfolioMay 14, 2024 | marketbeat.comThornburg Investment Management Inc. Sells 105,276 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Thornburg Investment Management Inc. reduced its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 38.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 170,802 shares of the bioMay 14, 2024 | marketwatch.comBioMarin Pharmaceutical to Discontinue Certain R&D Programs, Cut About 170 JobsMay 14, 2024 | msn.comEvercore ISI Group Initiates Coverage of BioMarin Pharmaceutical (BMRN) with Outperform RecommendationMay 14, 2024 | insidertrades.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Jean Jacques Bienaime Sells 20,000 SharesMay 13, 2024 | marketbeat.comJean Jacques Bienaime Sells 20,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) StockBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) Director Jean Jacques Bienaime sold 20,000 shares of the company's stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $81.62, for a total transaction of $1,632,400.00. Following the completion of the sale, the director now owns 474,994 shares in the company, valued at approximately $38,769,010.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.May 11, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 74,100 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Charles Schwab Investment Management Inc. boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 5.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,378,897 shMay 10, 2024 | marketbeat.comFisher Asset Management LLC Purchases New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Fisher Asset Management LLC acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 13,266 shares of the biotechnology company's stock, valued at approximatelyMay 9, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in May 2024May 8, 2024 | prnewswire.comBioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NVMay 7, 2024 | marketbeat.comNational Bank of Canada FI Sells 342,304 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)National Bank of Canada FI reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 56.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 268,607 shares of the biotechnology compMay 7, 2024 | insidertrades.comInsider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Sells 1,850 Shares of Stock Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Don’t make this retirement mistake (Ad)If you have over $100,000 in your 401K or IRA… Then listen closely… Your money is rotting away, and you might not even realize it. Reserve your seat here. BMRN Media Mentions By Week BMRN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BMRN News Sentiment▼1.270.76▲Average Medical News Sentiment BMRN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BMRN Articles This Week▼107▲BMRN Articles Average Week Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SRPT News Today TEVA News Today MRTX News Today VYGR News Today BIIB News Today ALNY News Today NBIX News Today INCY News Today UTHR News Today RGEN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BMRN) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored